Centinel Spine, a provider of integrated interbody fusion devices, has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its new Stalif Midline system.

The Stalif Midline integrated interbody fusion system offers both clinically validated technology and new convenience features, Centinel said.

The features include Lag Effect Fixation consistent with the principles of segmental fixation and Wolff’s Law and also contain Lumen Locking which guards against screw back-out.

Centinel chairman and chief executive officer John Viscogliosi said that the timing of the FDA clearance coincides with this year’s meetings of the North American Spine Society (NASS) and Congress of Neurological Surgeons (CNS) where they look forward to showcase Stalif Midline.